BioNTech stock faces a 59.5 percent Q2 revenue drop

Published on 10/04/2026 at 17:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech stock carries a Moderate Buy consensus from 19 brokerages and a USD 126.00 average target. Q3 results are scheduled for November 3, 2026.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech stock (ISIN US09075V1026) was last at USD 96.90 on Nasdaq on October 2, 2026, while the company is working through a 59.5 percent year-over-year revenue decline. MarketBeat reported on October 3, 2026, that analysts retain a Moderate Buy consensus despite the weak second-quarter figures.

Q2 revenue fell 59.5 percent

BioNTech reported USD 122.31 million in Q2 2026 revenue, down 59.5 percent from the same period a year earlier. The company also posted a USD 2.53 loss per share, missing the USD 2.40 consensus estimate by USD 0.13, according to MarketBeat in its October 3, 2026 report.

The comparison matters because the prior-year quarter produced a USD 1.60 loss per share, putting the latest result below both the earlier period and consensus. BioNTech's Q2 net margin was negative 63.54 percent, while its reported return on equity was negative 6.86 percent.

Analysts still see a 30.0 percent gap

The analyst view is more constructive than the latest income statement. The consensus covers 19 brokerages, with 12 Buy ratings, five Holds, one Sell and one Strong Buy, while the average 12-month target is USD 126.00, MarketBeat reported on October 3, 2026.

Against the USD 96.90 Nasdaq price on October 2, 2026, that consensus target stands 30.0 percent above the share price. The range remains wide: BioNTech stock has a 52-week low of USD 79.52 and a high of USD 124.00, so the current price sits USD 27.10 below the high.

CEO sale adds a second signal

CEO Ugur Sahin sold 17,000 shares at an average USD 97.46 in a transaction dated October 1, 2026, under a pre-arranged Rule 10b5-1 plan, according to MarketBeat on October 2, 2026. The disclosure adds an insider-activity counterpoint to the analyst target, although the transaction was executed under a pre-arranged plan.

BioNTech stock remains below its yearly high

BioNTech stock was last at USD 96.90 on Nasdaq on October 2, 2026, up USD 0.05, or 0.05 percent, from the prior close. The session volume was 681,350 shares and market capitalization was USD 24.3 billion on the same date.